phenotypeId,phenotypeName,referentConceptId,clinicalDescription,literatureReview,phenotypeNotes
133169000,Myelofibrosis,133169,"Overview: Rare blood cancer, a form of chronic leukemia were bone marrow is replaced by fibrous scar tissue losing its ability to produce normal blood cells. Primary (occurs on its own) or Secondary (as the result of a separate disease)Presentation: anemia, pale, enlarged spleen, portal HTN, nigt sweats, fever, itching, frequent infections, blood clots, bone or joint pain, bruising, and extramedullary hematopoiesisAssessment: Cliincal exam, CBC (elevated WBC and platelets and lower RBCs), Elevated levels of uric acid, bilirubin, and lactic dehydrogenase; gene mutation analysis - JAK2, CALR, or MPL mutation, bone marrow aspiration & biopsy, ultrasound (enlarged spleen), Myeloproliferative Neoplasm-Symptom Assessment: Form Total Symptom Score (MPN-SAF TSS)Plan: multikinase inhibitor (ruxolitinib), glucocorticoids, androgens, immunomodulators, chmoe and blood transfusions, if needed splenectomy or radiation therapy; allogenic hematopoietic stem cell transplantation (HSCT) is a potential cure  Prognosis: Serious & progressive disease, can progress to acute myeloid leukemia (AML); many factors to eval for Prognosis: - International Prognosis: scoring system (IPSS)","",""
